Avadel PharmaceuticalsAVDL
13F holders, Q4 2024 (December 31)3holders −2
0new positions
2sold out
$10.51avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding Avadel Pharmaceuticals plc (AVDL) in their 13F filings, down 2 from Q3 2024. 0 opened new positions and 2 sold out. The largest holders were Knoll Capital Management, LLC ($6.3M), Schulhoff & Co. Inc. ($1.4M) and Huntington National Bank ($16).
- Company
- Avadel Pharmaceuticals plc
- CUSIP
- 05337M104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $4.4M |
All 13F filers, Q3 2024 → Q4 2024: 333,000 shares sold, net −333,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Knoll Capital Management, LLC | 4.06% | No change | 600,000 | $6.3M |
| Schulhoff & Co. Inc. | 0.53% | No change | 137,000 | $1.4M |
| Huntington National Bank | 0.00% | No change | 1 | $16 |
"% of holder's portfolio" is AVDL's weight in each manager's 13F, not the share of Avadel Pharmaceuticals plc the manager owns.